Kuwait's War on ISIS and DNA
By Dawn Field,
Oxford University Press Blog
| 09. 03. 2015
Untitled Document
DNA testing and genomics is now so prevalent there are national genotyping platforms. Iceland became the first country in history to sequence the genomes of its population. Other countries are lining up.
The Faroe Islands, an autonomous region of Denmark, is sequencing its population of 50k. GenomeDenmark released its first 30 reference genomes. The Genome of the Netherlands project published a reference genome for the Dutch based on 750 genomes from two-parent-one child ‘trios’. Genomic England is working on a 100k genomes project. The US is interpreting a million genomes as part of Obama’s precision medicine initiative. The Korean Genome project aims to sequence all 50 million living Koreans. Yet more countries are sequencing to unravel the secrets of ancestry, such as Wales’s DNA Wales initiative. These national programmes are further complemented by the Personal Genome Project Global Network, now covering the US, UK, Canada and Austria.
Now Kuwait is changing the playing field. In early July, just days after the deadly Imam Sadiq mosque bombing claimed by ISIS, Kuwait ruled to instate...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...